INSR and neoplasm: BMS-754807, with dual IGF-1R/InsR tyrosine kinase inhibition, has promising anti-tumor activity against various cancers, including breast, pancreatic, and lung cancers (Awasthi et al. 2012; Hou et al. 2011; Zhang et al. 2023).